m7G(5')ppp(5')A RNA Cap Structure Analog, New England Biolabs

Supplier: New England Biolabs
S1405S S1405S S1405L S1405L
CA101227-242EA 1056 CAD
CA101227-242 101227-244 CA101227-244 101227-242
m7G(5')ppp(5')A RNA Cap Structure Analog, New England Biolabs
Nucleic Acid Reagents Nucleic Acid Modification and Labelling
The 5´terminal m7G cap present on most eukaryotic mRNAs promotes translation in vitro at the initiation level.

For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs for protein synthesis. Certain prokaryotic mRNAs containing a 5´ terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Also a cap requirement has been observed for splicing eukaryotic substrate RNAs. A method using E. coli RNA Polymerase primed with m7G(5´)ppp(5´)G or m7G(5´)ppp(5´)A for an efficient in vitro synthesis of capped RNAs has been developed by Contreas. Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m7G(5´)ppp(5´)G.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR